11. VIR-7831
Developers: GlaxoSmithKline (LON: GSK) and Vir Biotechnology (NSDQ: VIR)
Description: VIR-7831 (GSK4182136) is an anti-SARS-CoV-2 antibody that could be used to treat mild-to-moderate COVID-19 infections. The antibody can achieve high concentrations in the lungs.
Development status: The two companies have launched a Phase 3 clinical trial to study the safety and efficacy of VIR-7831 to treat hospitalized adults with COVID-19. The study, known as ACTIV-3, is part of a series of trials from the NIH.
VIR-7831 image drawn from an SEC filing.
In October, GSK stated that interim Phase 3 results could be available before the end of the year and that it expected results from the primary endpoint of the trial in the first quarter of 2021.
10 trends that will matter in pharma in 2021>>
Filed Under: clinical trials, Drug Discovery, Infectious Disease
Tell Us What You Think!
You must be logged in to post a comment.